Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome (COVIDIOL)

M

Maimónides Biomedical Research Institute of Córdoba

Status and phase

Completed
Phase 2

Conditions

SARS (Severe Acute Respiratory Syndrome)
Cytokine Release Syndrome
SARS-CoV 2
Cytokine Storm
COVID19

Treatments

Drug: BAT + Calcifediol
Drug: BAT

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT04366908
COVIDIOL

Details and patient eligibility

About

The administration of Calcifediol in patients with COVID-19, will reduce the development of SARS and the worsening of the various phases of the syndrome. Reducing at least 25% in ICU admission and death from the process, reducing days of hospitalization, facilitating the recovery of the same, acting significantly and positively, in any of its phases throughout the natural history of illness. As a treatment with extensive experience of clinical use, safe, inexpensive, and potentially very effective, it will have a highly efficient cost-benefit impact on the prevention of SARS.

Enrollment

517 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 and < 90 years
  • PCR confirmed diagnosis of COVID-19. As an alternative to PCR, a determination of antigens or any other test that in the future is considered equivalent to these in its diagnostic value may be accepted as evidence
  • Radiological image compatible with inflammatory pleuropulmonary exudate or patients with onset of symptoms in the last 7 days and with an uncomplicated respiratory infection for outpatient follow-up.
  • Signature of direct or delegated informed consent

Exclusion criteria

  • Being treated with Calcifediol or Cholecalciferol in any of its presentations and dosages
  • Intolerance or allergy to Calcifediol or its components
  • Pregnancy

Trial design

517 participants in 2 patient groups

Control - best available therapy
Active Comparator group
Description:
The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
Treatment:
Drug: BAT
Treatment
Experimental group
Description:
The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be Start: 2 capsules Days 3, 7, 14, 21, 28: 1 capsule
Treatment:
Drug: BAT + Calcifediol

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems